News Channels

03 Mar 2017 Otsuka Pharmaceutical to Acquire Neurovance, Inc.
03 Mar 2017 Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer
03 Mar 2017 BIOCAD: The first ever biosimilar of interferon beta-1a approved in Russia
03 Mar 2017 New Results from Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority versus Humira® in Treatment of Moderate to Severe Plaque Psoriasis
03 Mar 2017 PTC Therapeutics Announces Results from Pivotal Phase 3 Clinical Trial of Ataluren in Patients Living with Nonsense Mutation Cystic Fibrosis
03 Mar 2017 Karyopharm Announces Results from Interim Analysis of Phase 2 SOPRA Study Evaluating Selinexor in Relapsed/Refractory Acute Myeloid Leukemia
03 Mar 2017 MedImmune and Sanofi Pasteur form alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897
02 Mar 2017 Myovant Sciences Initiates Phase 3 Clinical Trial of Relugolix in Men with Advanced Prostate Cancer
02 Mar 2017 Findings published in Nature Communications show that mRNA-LNP encoding a neutralizing antibody protect humanized mice from HIV challenge
02 Mar 2017 Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study
02 Mar 2017 Synthon enters worldwide exclusive license and collaboration with Sanquin for immuno-oncology therapeutic leads modulating the CD47-SIRPα pathway
02 Mar 2017 Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid
02 Mar 2017 FDA approves Odactra for house dust mite allergies
02 Mar 2017 BLINCYTO® (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
02 Mar 2017 Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer without their Disease Returning Compared to Herceptin® and Chemotherapy
01 Mar 2017 Accera Announces Results of its First Phase 3 Study in Mild-to-Moderate Alzheimer’s Disease
01 Mar 2017 Audentes Therapeutics Announces Commencement of LUSTRO, a Clinical Assessment and Phase 1/2 Run-in Study of Patients with Crigler-Najjar Syndrome
01 Mar 2017 Adynxx Initiates ADYX-004, a Phase 2 Study of AYX1, Lead Compound for the Treatment of Post-Surgical Pain
01 Mar 2017 OMEICOS Announces First Closing of €8.3 Million Series B Financing Round and the Initiation of Phase 1 Clinical Trial
01 Mar 2017 FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing